Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
6.71
+0.07 (1.05%)
At close: Sep 22, 2026, 4:00 PM EDT
6.71
0.00 (0.00%)
After-hours: Sep 22, 2026, 4:54 PM EDT
Entrada Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Entrada Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $19. The average 1-year stock price forecast is 183.16% higher than the current stock price, while the lowest is $11 (+63.93%) and the highest is $25 (+272.58%).
Price Target: $19 (+183.16%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Entrada Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 7 | 7 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $23 | Buy | Reiterates | $23 | +242.77% | Sep 3, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $10 → $11 | Buy | Reiterates | $10 → $11 | +63.93% | Aug 12, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 10, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 5, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $20 → $17 | Buy | Maintains | $20 → $17 | +153.35% | Jun 5, 2026 |
Financial Forecast
Revenue This Year
12.17M
from 25.42M
Decreased by -52.14%
Revenue Next Year
22.86M
from 12.17M
Increased by 87.90%
EPS This Year
-3.79
from -3.47
EPS Next Year
-3.01
from -3.79
EPS and Forward PE are based on non-GAAP adjusted numbers.